| 作者 |
 从近期医药改革想到 |
 |
| 所跟贴 |
as long as a brand name drug has been challenged with paragraph IV, -- 游客 - (790 Byte) 2005-8-10 周三, 04:28 (347 reads) |
fishingshu
头衔: 海归少尉
加入时间: 2005/07/15
文章: 45
海归分: 2225
|
|
|
作者：fishingshu 在 项目找投资与合作 发贴, 来自【海归网】 http://www.haiguinet.com
1. Are you saying that patent challenge in China is a matter of formality? If so, how come we only see two such cases, viagra and avandia?
2. Regarding drug registration in China, is there any regulatory barrier? Or, what needs to be done other than pulling some strings?
And, Paragraph IV may not necessarilly mean invalidation. It's usually cheaper and more practical to design around patents, especially those pertaining to formulation. So the patent is still enforceable. That being said, all these only apply to the sitatuion in the US. Looks like our compatriots have been pretty creative in finding their own means. Viagra patent was invalidated based on a technicality, right?
作者：fishingshu 在 项目找投资与合作 发贴, 来自【海归网】 http://www.haiguinet.com
|
|
|
| 返回顶端 |
|
 |
|
| |
|
|
|
您不能在本论坛发表新主题, 不能回复主题, 不能编辑自己的文章, 不能删除自己的文章, 不能发表投票, 您 不可以 发表活动帖子在本论坛, 不能添加附件可以下载文件, |
|
|
